Live price temporarily unavailable.
Ocugen (OCGN) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $0 | $0 | $0 | $0 | $43.0K | $0 | $2.49M | $6.04M | $4.05M | $4.41M |
| Growth (year over year) | — | — | — | — | — | −100.0% | — | +142.6% | −32.8% | +8.8% |
| Operating income | −$30.3M | −$24.9M | −$16.1M | −$14.2M | −$21.3M | −$58.0M | −$89.1M | −$65.5M | −$54.8M | −$62.9M |
| Operating margin | — | — | — | — | −49500.0% | — | −3580.0% | −1085.7% | −1350.4% | −1425.7% |
| Net income | −$16.2M | −$26.4M | −$18.2M | −$20.2M | −$21.8M | −$58.4M | −$86.8M | −$63.1M | −$54.1M | −$67.8M |
| Net margin | — | — | — | — | −50748.8% | — | −3488.9% | −1045.0% | −1333.0% | −1537.4% |
| EPS (diluted) | −$2.18 | −$0.99 | −$0.79 | −$1.46 | −$0.31 | −$0.30 | −$0.40 | −$0.26 | — | — |
| Balance sheet | ||||||||||
| Cash and equivalents | $31.9M | $7.08M | $1.63M | $7.44M | $24.0M | $95.0M | $77.6M | $39.5M | $58.8M | $18.6M |
| Total assets | $36.1M | $11.0M | $2.45M | $16.8M | $27.4M | $105.8M | $108.6M | $64.5M | $82.4M | $43.5M |
| Total liabilities | $22.5M | $22.3M | $15.2M | $5.79M | $5.83M | $9.94M | $34.7M | $24.0M | $52.8M | $55.7M |
| Long-term debt | — | — | $1.02M | $1.07M | $1.82M | $1.71M | $2.29M | $2.80M | $27.3M | $27.5M |
| Shareholders' equity | $13.6M | $4.43M | −$12.7M | $11.0M | $21.6M | $91.2M | $74.0M | $40.6M | $29.6M | −$12.2M |
| Cash flow | ||||||||||
| Operating cash flow | −$25.7M | −$23.0M | −$11.6M | −$16.9M | −$14.7M | −$47.9M | −$60.1M | −$62.1M | −$42.1M | −$57.0M |
| Capital expenditure | $320.0K | $276.0K | $77.4K | $30.0K | $307.0K | $939.0K | $4.46M | $10.5M | $3.38M | $185.0K |
| Free cash flow | −$26.1M | −$23.3M | −$11.7M | −$16.9M | −$15.0M | −$48.9M | −$64.5M | −$72.5M | −$45.5M | −$57.1M |
| Share buybacks | — | — | $0 | $48.0K | $0 | $0 | — | — | — | — |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.14M | $764.0K | $1.48M | $1.37M | $1.75M | — | $1.53M | $1.49M |
| Growth (year over year) | −69.3% | −45.8% | +46.1% | +20.3% | +54.2% | — | +3.5% | +8.4% |
| Operating income | −$13.3M | −$13.8M | −$14.5M | −$13.8M | −$17.6M | — | −$17.8M | −$16.4M |
| Operating margin | −1166.5% | −1811.5% | −979.1% | −1004.7% | −1006.0% | — | −1163.7% | −1105.1% |
| Net income | −$13.0M | −$13.9M | −$15.3M | −$14.7M | −$20.1M | — | −$19.2M | −$24.9M |
| Net margin | −1141.7% | −1816.8% | −1036.5% | −1073.5% | −1144.5% | — | −1250.9% | −1671.8% |
| EPS (diluted) | — | — | −$0.05 | −$0.05 | — | — | −$0.06 | −$0.07 |
| Balance sheet | ||||||||
| Cash and equivalents | $39.0M | $58.8M | $37.8M | $27.0M | $32.9M | $18.6M | $31.9M | $100.1M |
| Total assets | $61.9M | $82.4M | $64.5M | $53.6M | $57.6M | $43.5M | $56.9M | $124.2M |
| Total liabilities | $21.3M | $52.8M | $48.5M | $50.5M | $54.1M | $55.7M | $51.1M | $140.8M |
| Long-term debt | $1.57M | $27.3M | $27.7M | $28.0M | $28.4M | $27.5M | $24.2M | $1.73M |
| Shareholders' equity | $40.6M | $29.6M | $15.9M | $3.05M | $3.53M | −$12.2M | $5.80M | −$16.6M |
| Cash flow | ||||||||
| Operating cash flow | −$11.3M | −$10.4M | −$19.4M | −$10.7M | −$12.9M | — | −$21.8M | −$12.2M |
| Capital expenditure | $507.0K | $13.0K | $16.0K | $43.0K | $91.0K | — | $6.00K | $21.0K |
| Free cash flow | −$11.8M | −$10.4M | −$19.4M | −$10.8M | −$13.0M | — | −$21.8M | −$12.2M |
From Ocugen's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Ocugen in our feed yet.